Drugs / BMS-986249
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03369223 | Dec 2017 → Nov 2024 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-05 | Bristol-Myers Squibb | Results Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer bms.com ↗
Anti–Cytotoxic T Lymphocyte Antigen-4 (CTLA 4) Probody BMS-986249 ± Nivolumab (NIVO) in Patients (pts) With Advanced Cancers: Updated Phase 1 Results |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-05 | Bristol-Myers Squibb | Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer bms.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986249 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03369223 ↗ |